Objective: Continuous positive airway pressure (CPAP) has been established as an effective treatment for obstructive sleep apnea-hypopnea syndrome (OSAHS). Recently, several auto-CPAP devices that can detect upper airway obstructive events and provide information about residual events while patients are on CPAP have come into clinical use. The purpose of this study was to compare the apnea-hypopnea index (AHI) determined by the S8 auto-CPAP device with the AHI derived by polysomnography in patients with OSAHS. Method: Consecutive patients with OSAHS titrated on S8 auto-CPAP were included. The correlation between AHI determined by manual scoring (AHI-PSG) and by S8 (AHI-S8) during an overnight in-hospital polysomnogram with the patient on CPAP was assessed. Furthermore, the apnea index (AI) and the hypopnea index (HI) were evaluated separately. Results: Seventy patients with OSAHS (94% men) were enrolled. The mean AHI on the diagnostic study was 51.9 ± 2.4. During the titration, this device markedly suppressed the respi-ratory events (AHI-PSG, 4.2 ± 0.4; AI, 1.9 ± 0.3; HI, 2.3 ± 0.3). On the other hand, the AHI-S8 was 9.9 ± 0.6 (AI-S8, 2.4 ± 0.3; HI-S8, 7.5 ± 0.4). There was a strong correlation between the overall AHI-PSG and the AHI-S8 (r = 0.85, p < 0.001), with a stronger correlation in the apnea component AI-PSG and the AI-S8 (r = 0.93, p < 0.001), whereas there was a weaker correlation between the HI-PSG and the HI-S8 (r = 0.67, p < 0.001). Conclusions: Using the same airflow signals as those of the CPAP device, a strong correlation between the AHI-PSG and the AHI-S8 was observed. However, the correlation was weakened when the analysis was limited to the HI.

No abstract

No abstract

Oxidative stress owing to an imbalance between reactive oxygen species and antioxidants, such as coenzyme Q10 (CoQ10), is a major contributor to male infertility. We investigated the effects of the reduced form of CoQ10 (ubiquinol) supplementation on semen quality in dogs with poor semen quality. Three dogs received 100 mg of ubiquinol orally once daily for 12 weeks. Semen quality, serum testosterone, and seminal plasma superoxide dismutase (SOD) activity were examined at 2-week intervals from 2 weeks before ubiquinol supplementation to 4 weeks after the treatment. Ubiquinol improved sperm motility, reduced morphologically abnormal sperm, and increased seminal plasma SOD activity; however, it had no effect on testosterone level, semen volume, and sperm number. Ubiquinol supplementation could be used as a non-endocrine therapy for infertile dogs.